GlobeStar Therapeutics GSTC · USD

Its shares trade under the ticker GSTC. It has been listed since 21 May 2011. In the fiscal year to 30 September 2020, it reported revenue of $100 and a net loss of $541,700. At that date it held total assets of $89,900 and shareholders' equity of −$659,200.

GlobeStar Therapeutics Corp. is a clinical stage biotechnology company, which engages in the manufacture and patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is headquartered in Richland, Washington. The company went IPO on 2011-05-21. The firm is focused on introducing a patented formulation of drugs for the treatment of Multiple Sclerosis and other neurodegenerative diseases. The firm owns the global license from the inventors, who are based in Italy. The firm has acquired a license for a patented method of treating neurodegenerative diseases such as Multiple Sclerosis by administering a synergistically effective amount of the composition to an individual suffering from neurodegeneration and treating neurodegeneration. GlobeStar Therapeutics is initiating discussions with the Food and Drug Administration (FDA) on clinical trial design in preparation for FDA submission and approval pathway.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. James KatzaroffChairman of the Board, President, Chief Executive Officer, Principal Executive Officer, Company Secretary, since 2020$462,773
• Mr. Robert ChicoskiChief Financial Officer, Treasurer, Principal Financial Officer$84,000
• Mr. William FarleyIndependent Director
• Mr. Steven PenderghastIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.